GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting

TAMPA, FL / ACCESSWIRE / November 12, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)…

GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers

BEVERLY HILLS, CA / ACCESSWIRE / October 21, 2020 / GT Biopharma, Inc.…

GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting

BEVERLY HILLS, CA / ACCESSWIRE / October 15, 2020 / GT Biopharma,…

GT Biopharma Announces Advisory Board Appointments

BEVERLY HILLS, CA / ACCESSWIRE / October 13, 2020 / GT Biopharma,…

Investors Are Scrambling To Get Ahead Of The Oncology Drug Market Boom; 1 Company Could Revolutionize The Industry

Designer Cancer Treatments Are The Next Opportunity For Investors; 1 Company Set To Pave The Way

GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update

BEVERLY HILLS, CA / ACCESSWIRE / September 22, 2020 / GT Biopharma,…